Model Informed Drug Development Archives | Page 12 of 46 | Certara

Press Release

Certara Opens New China Office in Shanghai

Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D …

CertaraNovember 9, 2020

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

Poster

THE RELATIONSHIP BETWEEN mRNA AND ACTIVITY FOLLOWING INDUCTION OF CYP3A4 AND CYP2B6 ACROSS A RANGE OF PROTOTYPICAL INDUCERS

CertaraAugust 28, 2019

Poster

Prediction of Prothrombin Time after Oral Administration of S-Warfarin in Different CYP2C9 Phenotypes in Asian and Caucasian populations using the Simcyp Simulator

CertaraAugust 23, 2019

Poster

Prediction of Midazolam Concentration Profile in Obese Adolescent Population Using Physiologically Based Pharmacokinetic model

CertaraAugust 23, 2019

Poster

Prediction of Enfuvertide Concentration-Time Profile in a Paediatric Population after Parenteral Administration Using a Physiologically Based Pharmacokinetic Model

CertaraAugust 23, 2019

Poster

Simulating the effect of anti-diabetic drugs on ATP-sensitive potassium (KATP) channels inhibition in a human cardiac cell model (ORd)

CertaraAugust 23, 2019

Poster

Application of a PBPK model for prediction of the DDI between Lorazepam and Probenecid.

CertaraAugust 22, 2019

Poster

What Sample Size to Use When Designing Paediatric Pharmacokinetic Studies? A Critical Analysis of “Precision Criteria”

CertaraAugust 22, 2019

Poster

T4.1 – Setting the framework for database and development of this database

CertaraAugust 22, 2019

© 2025 Certara. All Rights Reserved. | Privacy policy